Short answer
ENANTA PHARMACEUTICALS INC (ENTA) filed its Q1 2026 10-Q quarterly report on May 13, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $17M (down 46.2% year over year) with net income of −$13M.
Q1 2026 key financials · XBRL
- Revenue
- $17M
- −46.2% YoY · −7.8% QoQ
- Net income
- −$13M
- +70.9% YoY · −9.7% QoQ
- Operating margin
- -69.1%
- EPS (diluted)
- −$0.45
- +78.7% YoY · −7.1% QoQ
Source: XBRL data from the ENANTA PHARMACEUTICALS INC (ENTA) Q1 2026 10-Q on SEC EDGAR. USD.
ENANTA PHARMACEUTICALS INC Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No material changes to 10-K risk factors identified in the provided excerpt
- Liquidity risk: $227,012 in cash, cash equivalents, and marketable securities expected to fund operations for at least 12 months
- Financing risk: inability to obtain additional funding could force reductions or delays in research and development programs
- Royalty-obligation risk: $128,770 liability tied to MAVYRET/MAVIRET royalties with approximately 10.0% imputed interest
- Operational risk: product candidates require extensive preclinical testing, clinical trials, regulatory approvals, and compliance reporting before commercialization
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other ENANTA PHARMACEUTICALS INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.